2024-03-13 13:53:08 ET
More on Takeda Pharmaceutical
- Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds
- Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
- Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation
- Pfizer succeeds in Phase 3 trial for Adcetris in new lymphoma condition
- Takeda and India's Biological E. to accelerate access to dengue vaccine in endemic areas
Read the full article on Seeking Alpha
For further details see:
Takeda buoyed by mid-stage trial for immune disorder treatment mezagitamab